QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Contribute
Personal Finance
Alts
Best Real Estate Crowdfunding Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Cannabis
News
Earnings
Interviews
Deals
Regulations
Psychedelics
TV
YouTube
Video
Podcasts
Trading School
My Stocks
Tools
Premium
QQQ
––%
DIA
––%
SPY
––%
TLT
––%
GLD
––%
BTC/USD
––%
Clovis Oncology
(NASDAQ:CLVS)
0.8462
0.0647[8.28%]
Last update: 2:32PM
15 minutes delayed
Day High/Low0.76 - 0.86
52 Week High/Low0.7 - 7.24
Open / Close0.79 / -
Float / Outstanding141.1M / 143.9M
Vol / Avg.3.2M / 12M
Mkt Cap121.8M
P/E-
50d Avg. Price1.84
Div / Yield-
Payout Ratio-
EPS-0.44
Total Float141.1M

Clovis Oncology (NASDAQ:CLVS), Quotes and News Summary

Clovis Oncology (NASDAQ: CLVS)

Day High/Low0.76 - 0.86
52 Week High/Low0.7 - 7.24
Open / Close0.79 / -
Float / Outstanding141.1M / 143.9M
Vol / Avg.3.2M / 12M
Mkt Cap121.8M
P/E-
50d Avg. Price1.84
Div / Yield-
Payout Ratio-
EPS-0.44
Total Float141.1M
Benzinga - May 9, 2022, 6:27AM
Benzinga - May 6, 2022, 2:10PM
Benzinga - May 6, 2022, 12:18PM
Benzinga - May 5, 2022, 6:24AM
Benzinga - May 4, 2022, 10:47AM
Benzinga - May 4, 2022, 8:01AM
Benzinga - Apr 8, 2022, 2:54PM
Benzinga - Apr 8, 2022, 8:08AM
Benzinga - Apr 6, 2022, 1:15PM
Benzinga - Apr 4, 2022, 12:44PM
Benzinga - Mar 31, 2022, 9:22AM
Benzinga - Mar 31, 2022, 9:05AM
Benzinga - Mar 31, 2022, 7:29AM
Benzinga - Mar 31, 2022, 6:04AM
Benzinga - Mar 31, 2022, 6:02AM
Benzinga - Mar 16, 2022, 8:02AM
Benzinga - Feb 25, 2022, 8:04AM
load more
Sector: Health Care.Industry: Biotechnology
Clovis Oncology Inc is a biopharmaceutical company. It is focused on acquiring, developing and commercializing innovative anti-cancer agents in the United States, the EU, and additional international markets. The firm targets its development programs for the treatment of specific subsets of cancer populations. Its product candidates include Rucaparib and Lucitanib. Rucaparib is an oral small molecule inhibitor of poly ADP-ribose polymerase, is marketed in the United States for two indications specific to the recurrent epithelial ovarian, fallopian tube or primary peritoneal cancer whereas Lucitanib includes Rucaparib Combo and Nivolumab Combo.
Read More

Earnings

see more
Q2 2022Est.ActualSurprise
EPS
(EXPECTED)2022-08-03
REV
Q1 2022Est.ActualSurprise
EPS-0.430-0.440 -0.0100
REV36.970M34.247M-2.723M

Analyst Ratings

see more
DateAnalyst FirmAnalyst NameActionRatingAction Price Prior Price Target

Clovis Oncology Questions & Answers

Q
How do I buy Clovis Oncology (CLVS) stock?
A

You can purchase shares of Clovis Oncology (NASDAQ: CLVS) through any online brokerage.

View our list of the best stock brokerages.

Q
Who are Clovis Oncology's (CLVS) competitors?
Q
What is the target price for Clovis Oncology (CLVS) stock?
A

The latest price target for Clovis Oncology (NASDAQ: CLVS) was reported by HC Wainwright & Co. on Friday, May 6, 2022. The analyst firm set a price target for 0.00 expecting CLVS to fall to within 12 months (a possible -100.00% downside). 4 analyst firms have reported ratings in the last year.

Q
Current Stock Price for Clovis Oncology (CLVS)?
A

The stock price for Clovis Oncology (NASDAQ: CLVS) is $0.8462 last updated Today at May 16, 2022, 6:32 PM UTC.

Q
Does Clovis Oncology (CLVS) pay a dividend?
A

There are no upcoming dividends for Clovis Oncology.

Q
When is Clovis Oncology (NASDAQ:CLVS) reporting earnings?
A

Clovis Oncology’s Q2 earnings are confirmed for Wednesday, August 3, 2022.

Q
Is Clovis Oncology (CLVS) going to split?
A

There is no upcoming split for Clovis Oncology.

Q
What sector and industry does Clovis Oncology (CLVS) operate in?
A

Clovis Oncology is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.